Biotech venture capital may be pacing at a six-year low, but one startup just managed to raise a $300 million Series A mega-round.
The round was raised by ReNAgade Therapeutics, a new biotech developing what it hopes will be a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. MPM Capital’s BioImpact Capital and F2 Ventures co-led the Series A round, which is the biggest so far this year in the industry.
RNA medicine companies are one area where biotech financing is flourishing: Just last month, another RNA medicines company, Orbital Therapeutics, announced it had raised $270 million for a Series A.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect